Epstein–Barr virus reactivation in pediatric allogeneic stem cell transplant recipients: an 11-year experience on viral load and B lymphocyte monitoring strategy
These results could suggest the effectiveness of the approach used in providing pre-emptive therapy. The strategy adopted differs from that highlighted by other studies and allowed the reduction of the number of children who received rituximab. It has proven effective considering the low incidence rate of PTLD and reduces the risk of rituximab-related adverse events.
Authors
- Maria Santaniello (ORCID: https://orcid.org/0009-0002-1478-2894)
- Elio Castagnola (ORCID: https://orcid.org/0000-0002-5336-8429)
- Filomena Pierri (ORCID: https://orcid.org/0000-0002-0005-4127)
- Gianluca Dell’Orso (ORCID: https://orcid.org/0000-0002-6555-7219)
- Stefano Giardino (ORCID: https://orcid.org/0000-0002-7788-6407)
- Maura Faraci (ORCID: https://orcid.org/0000-0001-5715-501X)
- Giulia Ferrando
- Sara Pestarino
- Francesca Bagnasco (ORCID: https://orcid.org/0000-0003-1601-9518)
- Eddi Di Marco
Institutions
- Istituto Giannina Gaslini (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.3389/fimmu.2024.1492367
- Citations
- 1
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.28